Lung Cancer
From the Journals
Confirmation CT prevents unnecessary pulmonary nodule bronchoscopy
It’s probably a good idea to do a repeat CT the morning of a scheduled bronchoscopy to make sure the pulmonary nodule is still there, according to...
From the Journals
Noncancerous disease has a significant impact on lung cancer surgery survival
Following curative-intent resection of stage I NSCLC, noncancer-specific mortality is a significant competing event, with an increasing impact as...
Conference Coverage
VIDEO: Improved QOL an added benefit of pembrolizumab for NSCLC patients
First-line treatment of selected non–small-cell lung cancer patients with pembrolizumab produced significantly better quality of life, compared...
Conference Coverage
Toxicity high for SBRT in centrally-located lung tumors
VIENNA – Stereotactic body radiotherapy (SBRT) proved too toxic for many of patients recruited into a multinational phase II trial with centrally-...
Conference Coverage
c-Myc could be key to alisertib potential in small-cell lung cancer
VIENNA – The investigational agent alisertib plus paclitaxel improved progression-free survival, compared with paclitaxel plus placebo, in...
Conference Coverage
Durvalumab could offer option for difficult-to-treat NSCLC
VIENNA – In a heavily pretreated population of patients with non–small-cell lung cancer, the investigational checkpoint inhibitor durvalumab was...
From the Journals
KRAS-targeted T-cell therapy derails metastatic cancer
Adoptive transfer of cytotoxic T cells targeting a specific KRAS mutation (KRAS G12D) expressed by a metastatic colorectal cancer induced the...
Conference Coverage
Pembrolizumab proves promising for treating advanced SCLC
VIENNA – One-third of patients with extensive-stage small-cell lung cancer (SCLC) treated with the checkpoint inhibitor pembrolizumab achieved an...
Conference Coverage
VIDEO: Pivotal results nail osimertinib’s role in NSCLC
VIENNA – Osimertinib, a third-generation EGFR tyrosine kinase inhibitor that received U.S. marketing approval in November 2015 as second-line...
Conference Coverage
‘Vanishing’ role forecast for whole-brain irradiation for NSCLC metastases
VIENNA – Whole-brain irradiation plus chemotherapy can no longer be considered the standard of care in patients with multiple brain metastases...